XTL Biopharmaceuticals Completes Transformative Psyga Bio Acquisition and $1.5M Private Placement

summarizeSummary

XTL Biopharmaceuticals has finalized its acquisition of Psyga Bio, pivoting its core business to psychedelic medicine, and simultaneously closed a $1.5 million private placement to fund its new strategy.

check_boxKey Events · M&A and Partnerships · XTLB

• Acquisition Consummated

  XTL Biopharmaceuticals completed the acquisition of approximately 83.40% of Psyga Bio Ltd., an Israeli advanced biotechnology company focused on psychedelic and functional mushrooms.

• Strategic Business Pivot

  The acquisition transforms XTL into a dedicated psychedelic medicine company, leveraging Psyga Bio's clinical pipeline, licensed GMP manufacturing facility, and unique intellectual property library.

• Significant Dilution from Acquisition

  XTL issued American Depositary Shares (ADSs) representing approximately 33.36% of its post-issuance capital to Psyga Bio shareholders, with potential for an additional 25% based on clinical and commercial milestones.

• $1.5 Million Private Placement Closed

  A private placement of US$1,500,000 was completed at a purchase price of US$2.70 per ADS, including warrants, providing critical funding for the new operations.

auto_awesomeAnalysis · XTLB · Life Sciences

This filing confirms the closing of a major acquisition that fundamentally transforms XTL into a psychedelic biotechnology company. Concurrently, the company completed a $1.5 million private placement, which, while highly dilutive, provides essential capital to fund the new strategic direction and address previous financial and compliance challenges. This marks a definitive step in the company's efforts to secure its future and maintain its Nasdaq listing.